AUAUniversity Podcast Series: Episode No. 108

An Overview of PARPi & Adverse Event Management

This podcast was funded by and developed in collaboration with AstraZeneca.

Learning Objectives:
At the conclusion of this activity, participants will be able to:

1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.
2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.
3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.
4. 确定如何管理患者在服用PARP抑制剂时可能发生的不良事件。

Host: Victor Nitti, MD
Co-Host: Stephen Freedland, MD